Cargando…

Endocannabinoids and striatal function: implications for addiction-related behaviours

Since the identification and cloning of the major cannabinoid receptor expressed in the brain almost 25 years ago research has highlighted the potential of drugs that target the endocannabinoid system for treating addiction. The endocannabinoids, anandamide and 2-arachidonoyl glycerol, are lipid-der...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreira, Fabricio A., Jupp, Bianca, Belin, David, Dalley, Jeffrey W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams and Wilkins 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398317/
https://www.ncbi.nlm.nih.gov/pubmed/25369747
http://dx.doi.org/10.1097/FBP.0000000000000109
_version_ 1783230441618145280
author Moreira, Fabricio A.
Jupp, Bianca
Belin, David
Dalley, Jeffrey W.
author_facet Moreira, Fabricio A.
Jupp, Bianca
Belin, David
Dalley, Jeffrey W.
author_sort Moreira, Fabricio A.
collection PubMed
description Since the identification and cloning of the major cannabinoid receptor expressed in the brain almost 25 years ago research has highlighted the potential of drugs that target the endocannabinoid system for treating addiction. The endocannabinoids, anandamide and 2-arachidonoyl glycerol, are lipid-derived metabolites found in abundance in the basal ganglia and other brain areas innervated by the mesocorticolimbic dopamine systems. Cannabinoid CB1 receptor antagonists/inverse agonists reduce reinstatement of responding for cocaine, alcohol and opiates in rodents. However, compounds acting on the endocannabinoid system may have broader application in treating drug addiction by ameliorating associated traits and symptoms such as impulsivity and anxiety that perpetuate drug use and interfere with rehabilitation. As a trait, impulsivity is known to predispose to addiction and facilitate the emergence of addiction to stimulant drugs. In contrast, anxiety and elevated stress responses accompany extended drug use and may underlie the persistence of drug intake in dependent individuals. In this article we integrate and discuss recent findings in rodents showing selective pharmacological modulation of impulsivity and anxiety by cannabinoid agents. We highlight the potential of selective inhibitors of endocannabinoid metabolism, directed at fatty acid amide hydrolase and monoacylglycerol lipase, to reduce anxiety and stress responses, and discuss novel mechanisms underlying the modulation of the endocannabinoid system, including the attenuation of impulsivity, anxiety, and drug reward by selective CB2 receptor agonists.
format Online
Article
Text
id pubmed-5398317
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Lippincott Williams and Wilkins
record_format MEDLINE/PubMed
spelling pubmed-53983172017-04-27 Endocannabinoids and striatal function: implications for addiction-related behaviours Moreira, Fabricio A. Jupp, Bianca Belin, David Dalley, Jeffrey W. Behav Pharmacol Review Articles Since the identification and cloning of the major cannabinoid receptor expressed in the brain almost 25 years ago research has highlighted the potential of drugs that target the endocannabinoid system for treating addiction. The endocannabinoids, anandamide and 2-arachidonoyl glycerol, are lipid-derived metabolites found in abundance in the basal ganglia and other brain areas innervated by the mesocorticolimbic dopamine systems. Cannabinoid CB1 receptor antagonists/inverse agonists reduce reinstatement of responding for cocaine, alcohol and opiates in rodents. However, compounds acting on the endocannabinoid system may have broader application in treating drug addiction by ameliorating associated traits and symptoms such as impulsivity and anxiety that perpetuate drug use and interfere with rehabilitation. As a trait, impulsivity is known to predispose to addiction and facilitate the emergence of addiction to stimulant drugs. In contrast, anxiety and elevated stress responses accompany extended drug use and may underlie the persistence of drug intake in dependent individuals. In this article we integrate and discuss recent findings in rodents showing selective pharmacological modulation of impulsivity and anxiety by cannabinoid agents. We highlight the potential of selective inhibitors of endocannabinoid metabolism, directed at fatty acid amide hydrolase and monoacylglycerol lipase, to reduce anxiety and stress responses, and discuss novel mechanisms underlying the modulation of the endocannabinoid system, including the attenuation of impulsivity, anxiety, and drug reward by selective CB2 receptor agonists. Lippincott Williams and Wilkins 2015-02 2015-01-02 /pmc/articles/PMC5398317/ /pubmed/25369747 http://dx.doi.org/10.1097/FBP.0000000000000109 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by-nc-nd/3.0.
spellingShingle Review Articles
Moreira, Fabricio A.
Jupp, Bianca
Belin, David
Dalley, Jeffrey W.
Endocannabinoids and striatal function: implications for addiction-related behaviours
title Endocannabinoids and striatal function: implications for addiction-related behaviours
title_full Endocannabinoids and striatal function: implications for addiction-related behaviours
title_fullStr Endocannabinoids and striatal function: implications for addiction-related behaviours
title_full_unstemmed Endocannabinoids and striatal function: implications for addiction-related behaviours
title_short Endocannabinoids and striatal function: implications for addiction-related behaviours
title_sort endocannabinoids and striatal function: implications for addiction-related behaviours
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398317/
https://www.ncbi.nlm.nih.gov/pubmed/25369747
http://dx.doi.org/10.1097/FBP.0000000000000109
work_keys_str_mv AT moreirafabricioa endocannabinoidsandstriatalfunctionimplicationsforaddictionrelatedbehaviours
AT juppbianca endocannabinoidsandstriatalfunctionimplicationsforaddictionrelatedbehaviours
AT belindavid endocannabinoidsandstriatalfunctionimplicationsforaddictionrelatedbehaviours
AT dalleyjeffreyw endocannabinoidsandstriatalfunctionimplicationsforaddictionrelatedbehaviours